Research cluster: PROTumor / Subproject |
| Subproject 4: Quality control of development procedures, storage conditions and application protocols for therapeutic bacteria |
| Project time: 01.04.10-31.01.13 |
| Project leader: |
| Dr. Kurt Zimmermann, Symbio Gruppe GmbH & Co KG |
| The SHG group is responsible for the consulting and advisory service to all members in the consortium. The most important task is the translation of the experimental results into large-scale pharmaceutical production. Therefor, new manufacturing techniques for tumoricidal bacteria have to be developed and adapted by SymbioPharm. |
 |
| Furthermore, a pharmaceutical form of an antitumor drug based on living bacteria has to be designed. Finally, SHG will evaluate product stability, shelf life and storage conditions of therapeutic bacterial strains and will also produce preclinical and clinical test samples. |
 |
Funded by
New Brochure: Facetten der Genomforschung
Wissenschaftler entschlüsseln die Baupläne des Lebens (german; pdf; 12,3 Mb)
Wissenschaftler entschlüsseln die Baupläne des Lebens (german; pdf; 12,3 Mb)
